DIRECT FRUIT INTERNATIONAL LIMITED

Financial Health Score: A (Excellent)

Explanation: Direct Fruit International Limited exhibits the vital signs of a highly robust and financially fit organisation. The company demonstrates an exceptional immune system against market volatility through its substantial cash reserves, a strong and steady heartbeat of consistent equity growth, and an accelerating metabolism in profitability. While there is a mild congenital condition related to related-party dependencies, the overall financial wellness is outstanding.

1. Key Vital Signs

• Pulse Rate (Liquidity): Strong and Steady

  • Current Ratio: 1.52 (£2.79M current assets / £1.84M current liabilities)
  • Cash Reserves: £2.37M (representing 84% of total assets)
  • Interpretation: The company has an incredibly healthy cash flow. With £2.37M in the bank, Direct Fruit International could pay off all of its current liabilities tomorrow and still have over £500k in working capital. This is a highly liquid, cash-rich business.

• Blood Pressure (Profitability): Accelerating

  • Profit after Tax (2025): £89,206
  • Profit after Tax (2024): £36,164
  • Interpretation: The company’s profitability has more than doubled year-over-year. This surge in retained earnings shows a business that is not just generating revenue, but converting it efficiently to the bottom line.

• Bone Density (Capital Strength): Solidifying

  • Shareholders' Funds (2025): £956,790
  • Shareholders' Funds (2020): £831,602
  • Interpretation: Equity has grown consistently over the last five years, indicating that the business is retaining wealth and building a strong structural foundation rather than accumulating bad debt or eroding its base.

• Cholesterol Levels (Debt Profile): High "Good" Cholesterol, Manageable "Bad"

  • Total Liabilities: £1.84M
  • Trade Creditors: £503k
  • Other Creditors: £1.29M
  • Interpretation: While total liabilities look high, the company has zero long-term debt. The £1.29M in "other creditors" is likely comprised of director or group-related loans (given the related-party notes), acting more like patient, internal "good cholesterol" rather than aggressive, external debt. The company has more than enough cash to clear this if required.

2. Symptoms Analysis

• Symptoms of Strength: The most striking symptom is the sheer volume of cash relative to the balance sheet. A wholesale fruit and vegetable business typically requires high working capital, but Direct Fruit International operates with a massive cash cushion. Furthermore, the unqualified audit report with no emphasis of matter indicates a clean bill of health from the external examiner.
• Symptoms of Risk (Congenital Conditions): The accounts note that a director and shareholder is also a director and shareholder of the company's sole supplier. This creates a concentration risk and a related-party dependency. While currently under control, if the "sole supplier" catches a cold, Direct Fruit International could suffer from supply chain pneumonia.
• Management Changes: There has been a shift in the boardroom. Allan Lymer resigned as a director in October 2025, and Paul Lymer resigned as secretary in July 2026. While routine, changes in key personnel should be monitored like a mild chronic condition to ensure continuity of care.

3. Diagnosis

Diagnosis: Robust Financial Health with Benign Related-Party Dependency

The patient is in exceptional financial shape. The business operates an asset-light, cash-heavy model that provides immense financial resilience. The doubling of profit in the 2025 financial year suggests the business is operating at peak efficiency.

The £1.29M in "other creditors" within current liabilities initially appears as a symptom of high short-term debt stress. However, when cross-referenced with the £2.37M cash balance and the related-party transaction notes, this is diagnosed as benign—likely representing inter-company funding or director loans that sit on the balance sheet but are not pressing external debts. The true operational liabilities (trade creditors) are modest at £503k.

4. Prognosis & Recommendations

Prognosis: Excellent. The company is well-insulated against economic shocks, supply chain disruptions, or sudden cash flow demands. The trajectory of growing equity and rising profits suggests continued stable health.

Recommendations for Continued Financial Wellness:

1. Cardiovascular Workout (Cash Optimisation): While having £2.37M in cash is a fantastic safety net, keeping such a large portion of assets in low-yielding cash may represent an opportunity cost. Consider investing a portion of these reserves into higher-yield, short-term instruments or exploring strategic capital expenditure to drive future growth.
2. Vaccinate the Supply Chain (Diversification): The reliance on a sole supplier linked to a director is a structural vulnerability. Even with the best relationships, single-point-of-failure risks can be dangerous. Begin introducing secondary supplier relationships to build immunity against sudden supply disruptions.
3. Monitor "Other Creditors" (Regular Check-ups): Ensure that the £1.29M owed to other creditors is formally documented with clear, arm's-length repayment terms. Even if this is internal/group debt, formalising the terms prevents future disputes and ensures the liability is managed appropriately.
4. Maintain Dividend Health: The company paid £44,603 in dividends in 2025, up from £18,082 in 2024. Given the strong profit and cash position, this is highly sustainable. Continue balancing rewarding shareholders with retaining sufficient earnings for operational growth.